8 research outputs found
Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
AbstractAmong 810 consecutive hematopoietic stem cell transplantation (HSCT) patients, 679 survived more than 3 months and were evaluated for chronic GVHD. The aim of this study was to find predisposing factors increasing the risk of development of moderate-to-severe chronic GVHD. Many of the donors were HLA-identical siblings or related (n = 435), 185 were HLA-matched unrelated, and 59 were mismatched related or unrelated donors. Most of the patients had a hematological malignancy (n = 568), but 111 patients with a nonmalignant disease were included. Two hundred twenty-three patients (33%) developed mild, 41 (6%) moderate, and 15 (2.2%) severe chronic GVHD. The 5-year probability of development of moderate-to-severe chronic GVHD was 10%. We analyzed 30 potential risk factors for chronic GVHD. In the multivariate analysis, acute GVHD grades II to IV (relative hazard [RH], 2.30; 95% CI, 1.29- 4.10; P = .005), CML diagnosis (RH, 2.37; CI, 1.38-4.08; P = .002) and transplantation from an immunized female donor to a male recipient (RH, 2.16; CI, 1.14-4.11; P = .02) were independent risk factors for moderate-to-severe chronic GVHD. Recipient age also was significant (RH, 2.42; CI, 1.23-4.77; P = .01) if CML was not included in the analysis. In patients with no risk factors, the 5-year probability of development of moderate-to-severe chronic GVHD was 5%. In patients with 1 risk factor, the probability was 13%; 2 risk factors, 23%; and 3 risk factors, 45%. Among patients who developed chronic GVHD (n = 279), acute GVHD grades II to IV (RH, 2.18; CI, 1.23-3.86; P < .01) was the only predictive factor for moderate-to-severe chronic GVHD versus mild disease. Patients with previous acute GVHD grades II to IV may benefit from more aggressive initial treatment. This possibility would have to be examined in clinical trials.Biol Blood Marrow Transplant 2002;8(12):674-82
Reduced-intensity allogeneic hematopoietic stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European group for blood and marrow transplantation experience
Abstract Reduced-intensity conditioning (RIC) regimens for allogeneic hematopoietic stem cell transplantation (HCT) allowed the existence of an allogeneic cell-mediated antitumor effect in metastatic colorectal cancer (mCRC) to be explored. We report on 39 patients with progressing mCRC treated with different RIC regimens in a multicenter clinical trial of the European Bone Marrow Transplantation Group. Disease status at transplant was progressive disease (PD) in 31 patients (80%), stable disease (SD) in 6 (15%), and partial response (PR) in 2 (5%). All patients engrafted (median donor T cell chimerism of 90% at day +60). Transplant-related morbidities were limited. Grades II-IV acute graft-versus-host disease (aGVHD) occurred in 14 patients (35%) and chronic GVHD (cGVHD) in 9 patients (23%). Transplant-related mortality occurred in 4 patients (10%). The best tumor responses were: 1 complete response (CR) (2%), 7 PR (18 %), and 10 SD (26%), giving an overall disease control in 18 of 39 patients (46%). Allogeneic HCT after RIC is feasible; the collected results compared favorably in terms of tumor response with those observed using conventional approaches beyond second-line therapies. The study of an allogeneic cell based therapy in less advanced patients is warranted
Anti-tumour effect in solid tumours, tolerance and immune reconstition after allogeneic haematopoietic stem cell transplantation
Both in haematological malignancies and in disseminated solid tumours,
re-occurrence of the underlying disease is the main complication.
Allogeneic haematopoietic stem cell transplantation (HSCT) increases the
chance of cure compared to only chemotherapy in haematological
malignancies, but adds the risk of immunological complications such as
graft-versus-host disease (GVHD) and severe infections. Immunosuppressive
treatment is needed to prevent rejection of the graft and GVHD. The
reason for lower relapse incidence after allogeneic HSCT has been
attributed to a graft-versus-leukaemia (GVL) effect, which has also been
suggested to be present against solid tumours after HSCT.
The possible occurrence of a graft-versus-tumour (GVT) effect in
different solid tumours after allogeneic HSCT and the feasibility of a
reduced intensity conditioning (RIC) were investigated. Patients with
renal cell carcinoma (RCC, n=10), colon carcinoma (CC, n=6), breast
cancer (n=1) or a Klatskin tumour of the liver (n=1) were treated with
HSCT with a RIC consisting of Fludarabine and 2 Gray of total body
irradiation (TBI). During the study, four patients died of
transplantation-related complications between 45 and 160 days after HSCT
and three patients died of tumour progression 92-323 days after HSCT.
Almost total tumour regression was seen in the first patient with CC, but
he died of pneumonia 4 months after HSCT. Partial responses in the lungs
of one additional patient with CC and two patients with RCC, were seen.
Among 624 patients receiving transplants between 1977-1997 at Huddinge
Hospital, 254 patients surviving more than 12 months, were
retrospectively analysed regarding clinical tolerance, that was defined
as the absence of GVHD or rejection after withdrawal of
immunosuppression. Patients who did not develop GVHD had discontinued
immunosuppression according to the protocols. Children discontinued
immunosuppression faster than adults and male recipients with immunised
female donors discontinued immunosuppression later. Acute GVHD was
associated with longer time to withdrawal of immunosuppression. In
multivariate analysis, a high donor age, donation from an immunised
female donor to a male recipient, and acute GVHD grades II-IV were
associated with longer time to clinical tolerance.
Immune recovery analysed by diversity of the T cell receptor (TcR) and
the B cell immunoglobulin heavy chain (IgH) using spectratyping of the
third complementarity determining region (CDR3) was analysed in 24
patients after RIC (n=13) and myeloablative (n=11) HSCT. Reconstitution
of diversity of the CDR3 region was significantly delayed in the IgH
while significantly faster in the TcR after RIC HSCT compared to
myeloablative HSCT even though differences were small. Patients in the
RIC group were significantly older (54 vs. 42, p<0.05) and had slightly
more viral infections including asymptomatic CMV infection (p<0.05). RIC
patients also had a tendency for more chronic GVHD (ns, p=0.12). Immune
function in vitro was tested by lymphocyte stimulation at 3, 6, and 12
months after HSCT. Decreased responses to CMV and VZV antigens were seen
in patients suffering from acute GVHD grade II, compared to the healthy
donors. Patients in the RIC group had significantly lower responses to
concanavalin (Con-A), phytohemagglutinin (PHA), and Staph. aureus protein
A (SpA) during the first six months after RIC HSCT while patients in the
myeloablative group only showed lower responses to Con-A at three months,
compared to the healthy donors.
In conclusion, RIC HSCT is feasible in haematological diseases and solid
tumours. A GVT effect seems to exist in RCC and CC but has to be
enhanced. Most patients receiving HLA-identical stem cells are tolerant
within two years after HSCT. The B cell and T cell repertoires are skewed
during the first year after allogeneic HSCT and immune reconstitution
after HSCT with myeloablative and RIC conditioning seem to be comparable.
Individual factors such as GVHD, age and infections are probably more
important for immune reconstitution than type of conditioning